Continuing Pharmacy Education / CE Master List / NKOTB: New and Emerging Roles for GLP-1-Based Medications -RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

NKOTB: New and Emerging Roles for GLP-1-Based Medications -RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the 2025 CE Finale Encore Webinars.

 

* The information below is current as of the time of the presentation in 12/2025. This is a very active and rapidly-changing area of research so the information may have changed by the time the audience member watches this presentation in the future.

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

  • List recent FDA-approved indications for GLP-1-based medications
  • Recognize proposed mechanisms by which GLP-1-based medications may impact conditions beyond type 2 diabetes and adiposity-based chronic disease
  • Describe key findings from major clinical trials evaluating new therapeutic potential of GLP-1-based medications

Release and Expiration Dates

Released:  December 19, 2025
Expires:  December 19, 2028

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-25-065-H01-P

Session Code

25RW65-GLP35

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-25-065-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Khanh Dang, PharmD, CDCES, FNAP
Clinical Professor
UConn School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Dang has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

1. Which of the following GLP-1-based medication has an FDA indication for reducing risk sustained eGFR decline, end-stage kidney disease and CV death in adults with type 2 diabetes mellitus and CKD?
A. dulaglutide
B. semaglutide
C. tirzepatide

*

2. Which of the following GLP-1-based medication has an FDA indication for obstructive sleep apnea (OSA)?
A. dulaglutide
B. semaglutide
C. tirzepatide

*

3. Which of the following mechanisms contributes to the cardiovascular risk reduction observed with GLP-1-based medications?
A. Direct blockade of angiotensin II receptors and weight loss
B. Improved endothelial function, decreased blood pressure, and weight loss
C. Increasing sympathetic nervous system activity

*

4. In the FLOW study, which supported semaglutide’s recent FDA label approval for kidney risk reduction, the primary composite endpoint (kidney failure, ≥50% sustained eGFR reduction, or kidney/cardiovascular death) was reduced by ____ compared to placebo.
A. ~10%
B. ~25%
C. ~50%

*

5. Which patient population was enrolled in the SURMOUNT-OSA study?
A. Adults with obstructive sleep apnea and normal body weight
B. Adults with BMI of 30 and higher and obstructive sleep apnea, with or without positive airway pressure therapy
C. Adults with central sleep apnea due to neurologic disease, receiving with positive airway pressure therapy

*

6. Which of the following is a proposed mechanism of how GLP-1-based medications can lead to both renal protection and improvement in metabolic-dysfunction steatohepatitis (MASH)?
A. Decreased inflammation
B. Increased insulin resistance
C. Increased blood pressure

Video